Verapamil pretreatment before aortic cross-clamping in patients undergoing coronary artery bypass graft.
In 12 of 22 patients with coronary artery disease undergoing elective coronary artery bypass graft (CABG), verapamil (0.075 mg/kg body weight) pretreatment was given on initiation of cardiopulmonary bypass (CPB) before aortic cross-clamping (ACC), whereas no verapamil was used in 10 control patients. The volume of cardioplegia solution required to achieve and maintain cardiac asystole during ACC while on CPB was not significantly different in the two groups. After the release of ACC, the energy of direct current countershock required for defibrillation, the incidence of heart block, and the need for pacemaker were not significantly different. However, defibrillation was more readily achieved by a single countershock in the verapamil group than in the control group. Also, the incidence of ST segment changes after defibrillation was significantly lower in the verapamil group, suggesting that verapamil pretreatment before ACC may potentiate the myocardial preservation achieved by the cardioplegia, and hence may decrease the incidence of ischemic changes during the critical reperfusion period.
D001011:Aorta; D003250:Constriction; D001026:Coronary Artery Bypass; D004341:Drug Evaluation; D004554:Electric Countershock; D004562:Electrocardiography; D006324:Heart Arrest, Induced; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D011292:Premedication; D014700:Verapamil
D014700:Verapamil